figshare
Browse
ipgm_a_1401421_sm2870.jpg (55.48 kB)

The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis

Download (55.48 kB)
figure
posted on 2017-11-14, 18:17 authored by Junteng Zhou, Qi Zhang, Yushu Wang, Peijuan Gao, Decai Chen

Background: Cardiovascular disease (CVD) is the major cause of morbidity and mortality worldwide. Anacetrapib may be a new treatment option that has a cardiovascular benefit for the management of dyslipidemia.

Objective: The aim of our current study was to perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) assessing the effect and safety of anacetrapib in the treatment of dyslipidemia.

Methods: We systematically searched PubMed, Embase, and Cochrane Library database from their inception to 5 October 2017, with the terms: ‘anacetrapib’ and ‘placebo’. From 287 initial citations, 10 studies including 34781 patients with dyslipidemia were included in the final systematic review and meta-analysis.

Results: Pooled results showed that anacetrapib significantly increased high density lipoprotein cholesterol (HDL-C) [weighted mean differences (WMD) 53.07, 95% confidence interval (95% CI) 46.79 to 59.36] and apolipoprotein AI (ApoAI) (WMD 53.44, 95% CI 45.72 to 61.16). Our study also showed that anacetrapib significantly reduced low density lipoprotein cholesterol (LDL-C) (WMD −32.99; 95% CI −37.13 to −28.86), Non-HDL-C (WMD −39.19; 95% CI −52.22 to −26.16), triglycerides (TG) (WMD −9.97; 95% CI −10.54 to −9.41), apolipoprotein B (ApoB) (WMD −22.55; 95% CI −28.56 to −16.54) and lipoprotein a [LP(a)] (WMD −13.35; 95% CI −18.31 to −8.39). Our results demonstrated that there was no significant difference in all the following adverse events between the anacetrapib group and placebo group: [hepato-toxicity (OR 0.90, 95% CI: 0.75 to 1.07); musculoskeletal injury (OR 1.01, 95% CI: 0.88 to 1.15); drug-related adverse event (OR 1.00, 95% CI: 0.96 to 1.05); drug-related withdrawn (OR 1.01, 95% CI: 0.95 to 1.08)].

Conclusions: Although further studies are needed, our findings clearly offer support to the use of anacetrapib in the clinical management of patients with dyslipidemia.

Funding

This paper was not funded.

History

Usage metrics

    Postgraduate Medicine

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC